Graves Orbitopathy Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017-2021 and Forecast 2022-2028

$ PRICE - $ 3,000.00$ 8,900.00

Graves Orbitopathy Market: By Drug Class (Iodine and Iodides, Ionic Inhibitors, Radioactive Iodine, Beta Blockers, Thioamides and Corticosteroids), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Others) and Geography 

 

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

Graves Orbitopathy Market size is expected to be valued at USD million in 2022, growing at a significant CAGR of x% during 2022–2028. Graves’ ophthalmopathy is also called as thyroid-associated orbitopathy (TAO) and thyroid eye disease (TED), Graves’ orbitopathy (GO) is autoimmune inflammatory disorder of the tissues of periorbit and orbit that is characterized by the retraction of upper eyelid, lagging, swelling and redness of lid, bulging of eyes and conjunctivitis. Most commonly occurs in the individuals having Graves’ disease, and less commonly in the individuals having Hashimoto’s thyroiditis, or in the people with euthyroid. It is a part of systemic process of variable expression in skin, thyroid and eyes that is caused by the autoantibodies which binds to the tissues of these organs. Autoantibodies targets the fibroblasts in the eye muscles and fibroblasts can be differentiated into the fat cells (adipocytes). Muscles and fat cells expands and get inflammation. As per Wickham study in England, in 2016, Graves’ disease is accounted for 0.5 cases per 1000 persons, with high incidence rate in people with age of 40 to 60. Graves’ disease is the high prevalent autoimmune disorder in U.S After Hashimoto thyroiditis. In 2016, as per research study of PREGO (presentation of Graves orbitopathy), incidence of Graves’ orbitopathy in Europe was 10-30/10,000 human annually. However, severity and the incidence of the Graves’ disease in Europe was observed to decline to 2.10/10,000/year. Iodine-131 is used in radioactive iodine ablation (RIA) used to remove whole or a part of thyroid gland, which results in preventing the excessive production of thyroid hormone. Subtotal thyroidectomy used for the removal of thyroid gland is the most invasive treatment option.

Key Developments:

In September 2014, Avalon Ventures and GlaxoSmithKline plc launced two new companies with US $10 Mn each in series a financing and R&D support companies include Silarus Therapeutics- developing treatments for anaemia and iron overload disorders and Thyritope Biosciences- developing treatments for grave’s orbitopathy

 

Graves Orbitopathy Market

MARKET SUMMARY
-
x%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– x%
  • Largest Market– Asia Pacific
  • Fastest Growing Market–  North America

Graves Orbitopathy Market

  • The graves orbitopathy market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • The graves orbitopathy market is segmented based on based on drug class, distribution channels and geography.
Key Players
  • GlaxoSmithKline plc (U.K.),
  • Allergan, plc.(Ireland)
  • RLC LABS (U.S.),
  • AbbVie, Inc.( U.S.),
  • ylan N.V.( U.S.),
  • Pfizer, Inc. (U.S.),

 

Graves Orbitopathy Market Dynamics

Increase in incidence and prevalence of thyroid disorders, availability of appreciative reimbursement policies for the treatment, and growing awareness regarding the complications related to thyroid disorders are some of the factors driving Graves’ disease market. Side effects associated with drugs are one of the restraints for the graves orbitopathy market.


North-America Got Significant Share

Graves Orbitopathy Market

On the basis of geographical regions, the graves’ orbitopathy market is segmented as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected as major market for the disorders related to thyroid gland followed by Europe. Asia-Pacific is expected to be as a rapidly growing market due to rise in thyroid gland disorders, rise in health care investments, growing awareness regarding hyperthyroidism, and different alternative treatments availability.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The graves orbitopathy market report provides granular level information about the market size, regional market share, historic market (2017-2021), and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Graves Orbitopathy Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content

1. Executive Summary
2. Global Graves Orbitopathy Market Introduction
2.1. Global Graves Orbitopathy Market – Taxonomy
2.2. Global Graves Orbitopathy Market –Definitions
2.2.1. Drug Class
2.2.2. Distribution Channel
3. Global Graves Orbitopathy Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Graves Orbitopathy Market Dynamics – Factors Impact Analysis
3.6. Global Graves Orbitopathy Market – Regulations
3.6.1. U.S.
3.6.2. Europe
3.6.3. Japan
4. Global Graves Orbitopathy Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. Global Graves Orbitopathy Market, By Drug Class, 2017 – 2021 and Forecast, 2022 – 2028
5.1. Iodine and Iodides
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Ionic Inhibitors
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Radioactive Iodine
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Beta Blockers
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Thioamides
5.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Corticosteroids
5.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. Global Graves Orbitopathy Market Forecast, By Distribution Channel, 2017 – 2021 and Forecast, 2022 – 2028
6.1. Hospital Pharmacies
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Retail Pharmacies
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Others
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global Graves Orbitopathy Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028
7.1. North America
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Graves Orbitopathy Market – Opportunity Analysis Index, By Drug Class, By Distribution Channel, and Region, 2022 – 2028
8. North America Graves Orbitopathy Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
8.1. Drug Class Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.1.1. Iodine and Iodides
8.1.2. Ionic Inhibitors
8.1.3. Radioactive Iodine
8.1.4. Beta Blockers
8.1.5. Thioamides
8.1.6. Corticosteroids
8.2. Distribution Channel Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Others
8.3. Country Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.3.1. U.S.
8.3.2. Canada
8.4. North America Graves Orbitopathy Market – Opportunity Analysis Index, By Drug Class, By Distribution Channel, and Country, 2022 – 2028
8.5. North America Graves Orbitopathy Market Dynamics – Trends
9. Europe Graves Orbitopathy Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
9.1. Drug Class Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Iodine and Iodides
9.1.2. Ionic Inhibitors
9.1.3. Radioactive Iodine
9.1.4. Beta Blockers
9.1.5. Thioamides
9.1.6. Corticosteroids
9.2. Distribution Channel Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Hospital Pharmacies
9.2.2. Retail Pharmacies
9.2.3. Others
9.3. Country Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Russia
9.3.7. Poland
9.3.8. Rest of Europe
9.4. Europe Graves Orbitopathy Market – Opportunity Analysis Index, By Drug Class, By Distribution Channel and Country, 2022 – 2028
9.5. Europe Graves Orbitopathy Market Dynamics – Trends
10. Asia-Pacific Graves Orbitopathy Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
10.1. Drug Class Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Iodine and Iodides
10.1.2. Ionic Inhibitors
10.1.3. Radioactive Iodine
10.1.4. Beta Blockers
10.1.5. Thioamides
10.1.6. Corticosteroids
10.2. Distribution Channel Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Hospital Pharmacies
10.2.2. Retail Pharmacies
10.2.3. Others
10.3. Country Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
10.3.1. Japan
10.3.2. China
10.3.3. India
10.3.4. ASEAN
10.3.5. Australia & New Zealand
10.3.6. Rest of Asia-Pacific
10.4. Asia-Pacific Graves Orbitopathy Market – Opportunity Analysis Index, By Drug Class, By Distribution Channel and Country, 2022 – 2028
10.5. Asia-Pacific Graves Orbitopathy Market Dynamics – Trends
11. Latin America Graves Orbitopathy Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
11.1. Drug Class Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Iodine and Iodides
11.1.2. Ionic Inhibitors
11.1.3. Radioactive Iodine
11.1.4. Beta Blockers
11.1.5. Thioamides
11.1.6. Corticosteroids
11.2. Distribution Channel Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Hospital Pharmacies
11.2.2. Retail Pharmacies
11.2.3. Others
11.3. Country Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Argentina
11.3.4. Venezuela
11.3.5. Rest of Latin America
11.4. Latin America Graves Orbitopathy Market – Opportunity Analysis Index, By Drug Class, By Distribution Channel and Country, 2022 – 2028
11.5. Latin America Graves Orbitopathy Market Dynamics – Trends
12. Middle East and Africa Graves Orbitopathy Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
12.1. Drug Class Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Iodine and Iodides
12.1.2. Ionic Inhibitors
12.1.3. Radioactive Iodine
12.1.4. Beta Blockers
12.1.5. Thioamides
12.1.6. Corticosteroids
12.2. Distribution Channel Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Hospital Pharmacies
12.2.2. Retail Pharmacies
12.2.3. Others
12.3. Country Analysis (2017 – 2021) and Forecast (2022 – 2028) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Gulf Cooperation Council (GCC) Countries
12.3.2. Israel
12.3.3. South Africa
12.3.4. Rest of MEA
12.4. MEA Graves Orbitopathy Market – Opportunity Analysis Index, By Drug Class, By Distribution Channel and Country, 2022 – 2028
12.5. MEA Graves Orbitopathy Market Dynamics – Trends
13. Competition Landscape
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Drug Class & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Abbott Laboratories (U.S.)
13.2.2. Alimera Sciences (U.S.)
13.2.3. Allergan plc (Ireland.)
13.2.4. Ampio Pharmaceuticals. (U.S.)
13.2.5. Bayer AG (Germany)
13.2.6. F. Hoffmann-La Roche (Switzerland)
13.2.7. Novartis AG (Switzerland)
13.2.8. Pfizer Inc. (U.S.)
13.2.9. Regeneron Pharmaceuticals Inc. (U.S.)
13.2.10. Valeant (Canada)
14. Research Methodology
15. Key Assumptions and Acronyms

Report

Company Profile

  • Abbott Laboratories (U.S.)
  • Alimera Sciences (U.S.)
  • Allergan plc (Ireland.)
  • Ampio Pharmaceuticals. (U.S.)
  • Bayer AG (Germany)
  • F. Hoffmann-La Roche (Switzerland)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (U.S.)
  • Regeneron Pharmaceuticals Inc. (U.S.)
  • Valeant (Canada)

Description

Graves Orbitopathy Market size is expected to be valued at USD million in 2022, growing at a significant CAGR of x% during 2022–2028. Graves’ ophthalmopathy is also called as thyroid-associated orbitopathy (TAO) and thyroid eye disease (TED), Graves’ orbitopathy (GO) is autoimmune inflammatory disorder of the tissues of periorbit and orbit that is characterized by the retraction of upper eyelid, lagging, swelling and redness of lid, bulging of eyes and conjunctivitis. Most commonly occurs in the individuals having Graves’ disease, and less commonly in the individuals having Hashimoto’s thyroiditis, or in the people with euthyroid. It is a part of systemic process of variable expression in skin, thyroid and eyes that is caused by the autoantibodies which binds to the tissues of these organs. Autoantibodies targets the fibroblasts in the eye muscles and fibroblasts can be differentiated into the fat cells (adipocytes). Muscles and fat cells expands and get inflammation. As per Wickham study in England, in 2016, Graves’ disease is accounted for 0.5 cases per 1000 persons, with high incidence rate in people with age of 40 to 60. Graves’ disease is the high prevalent autoimmune disorder in U.S After Hashimoto thyroiditis. In 2016, as per research study of PREGO (presentation of Graves orbitopathy), incidence of Graves’ orbitopathy in Europe was 10-30/10,000 human annually. However, severity and the incidence of the Graves’ disease in Europe was observed to decline to 2.10/10,000/year. Iodine-131 is used in radioactive iodine ablation (RIA) used to remove whole or a part of thyroid gland, which results in preventing the excessive production of thyroid hormone. Subtotal thyroidectomy used for the removal of thyroid gland is the most invasive treatment option.

Key Developments:

In September 2014, Avalon Ventures and GlaxoSmithKline plc launced two new companies with US $10 Mn each in series a financing and R&D support companies include Silarus Therapeutics- developing treatments for anaemia and iron overload disorders and Thyritope Biosciences- developing treatments for grave’s orbitopathy

 

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX